Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

New England Journal of Medicine
December 31, 2020 Vol. 383 No. 27
http://www.nejm.org/toc/nejm/medical-journal

 

Original Articles
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Fernando P. Polack, M.D., et al for the C4591001 Clinical Trial Group
Conclusions
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728)